Observation of the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection with ColiFin 1Mio I.E. or ColiFin 2Mio I.E.

• Conditions: Chronic infection with Pseudomonas aeruginosaCystic fibrosis; E84; B96.5; Cystic fibrosis; Pseudomonas (aeruginosa) as the cause of diseases classified to other chapters

• Registration Number: DRKS00009540
• Lead Sponsor: PARI Pharma GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-19
• Study Completion: 2017-12-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Chronic pulmonary infections due to Pseudomonas aeruginosa in adult and paediatric patients with cystic fibrosis

Exclusion Criteria

No chronic pulmonary infections due to Pseudomonas aeruginosa in adult and paediatric patients with or without cystic fibrosis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Goal of this non-interventional study is to gain data on the prescription behaviour for ColiFin.

Secondary Outcome Measures

Name	Time	Method
Further more detailed perception of the therapy with ColiFin 1Mio./2Mio. I.E. within the authorised indication in the routine practise is expected.